Birmingham, West Midlands -- (SBWIRE) -- 12/19/2013 -- Value Penny Stocks issues special report on Amarin Corporation plc (ADR) (NASDAQ:AMRN), News Corp (NASDAQ:NWSA), Generex Biotechnology Corporation (OTCMKTS:GNBT), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Amarin Corporation plc (ADR) (NASDAQ:AMRN) opened its last trade at the price of $1.61. Its closing price was $1.60 after losing -0.62% for the day. The company traded with the total volume of 2,622,171 shares, while its average trading volume remained 5.07 million shares. The beta of this stock stands at 1.08. Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids.
Has AMRN Found The Bottom and Ready To Move Up? Find Out Here
News Corp (NASDAQ:NWSA) percentage change surged 0.86% to close at $17.50 with the total traded volume of 2,539,208 shares, along with average volume of 4.05 million shares. The 52 week range of the stock remained $14.39 - $17.97, while its day lowest price was $17.07. The share price hit the day highest price of $17.53. News Corporation, a media and information services company, focuses on creating and distributing authoritative and engaging content to consumers and businesses worldwide. The company operates through five segments: News and Information Services, Cable Network Programming, Digital Real Estate Services, Book Publishing, and Other.
For How Long NWSA’s Gloss will Attract Investors? Find out via this report
Generex Biotechnology Corporation (OTCMKTS:GNBT) traded on volume of 2.51 million shares in the last session against average volume of 1.83 million shares. The company started its trading session with the price of $0.03 and closed at $0.0290. Generex Biotechnology Corporation, a development stage company, is engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
How Should Investors Trade GNBT Now? Don’t Miss out a Special Trend Analysis
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) started its last trading session with the price of $6.87 and closed at $7.02 by scoring 8.33%. The stock traded with total volume of 2,480,660 shares, while the average trading volume remained 837,143.00 shares. The beta value of this stock stands at 3.03. Day range for the stock was $6.60 - $7.15. BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry.
Why Should Investors Buy BCRX After The Recent Gain? Just Go Here and Find Out
About Value Penny Stocks
Value Penny Stocks was made by Two Active traders, Steve and Wilson, whom have made a platform for traders in order to provide traders the #1 Penny Stock Newsletter which actually gives value to your money and makes your portfolio full of profits. We concentrate on small cap stocks that trade on NYSE, NASD, AMEX, OTCBB, and OTC exchanges. These are usually stocks that will trade under $5 a share and offer the utmost potential profit on your short or long term investment. We also devote ourselves to understanding the overall market situations and use this knowledge in order to gain a better perception during our stock picking decisions.
We at ValuePennyStocks.com are engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Please Read Our Full Disclaimer at: http://www.valuepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)